Humana’s second quarter results reflected operational execution and continued focus on long-term strategic goals. Management highlighted that customer growth and operational cost reductions were central to the quarter’s performance, citing progress in clinical and operational initiatives. CEO James Rechtin pointed to tangible improvements in Stars program metrics and emphasized the impact of centralizing utilization management and expanding outsourcing for greater efficiency. CFO Celeste Mellet noted that medical and pharmacy cost trends remained in line with internal assumptions, with cost favorability concentrated among value-based care members. Management’s commentary avoided any shift to a negative or uncertain tone, instead focusing on how operational changes are driving intended outcomes.
Is now the time to buy HUM? Find out in our full research report (it’s free for active Edge members).
Humana (HUM) Q2 CY2026 Highlights:
- Revenue: $40.87 billion vs analyst estimates of $40.63 billion (26.2% year-on-year growth, 0.6% beat)
- Adjusted EPS: $7.61 vs analyst estimates of $7.00 (8.8% beat)
- Management reiterated its full-year Adjusted EPS guidance of $9 at the midpoint
- Operating Margin: 3.3%, in line with the same quarter last year
- Customers: 17.91 million, up from 17.71 million in the previous quarter
- Market Capitalization: $43.49 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Humana’s Q2 Earnings Call
- Justin Lake (Wolfe Research) asked about the magnitude and timeline for margin improvement from 2026 to 2028, especially through Medicare Advantage bids. CFO Celeste Mellet explained that specific progress depends on membership mix, but confirmed meaningful gains are expected in 2027, with contingency measures in place for cost trends and new drug impacts.
- Jason Cassorla (Guggenheim Partners) inquired about inpatient cost trends and site-of-service initiatives. Mellet noted favorability in inpatient trends, while CEO James Rechtin described efforts to guide members toward lower-cost, higher-quality care sites through benefit design and education.
- Stephen Baxter (Wells Fargo) questioned the representativeness of the Stars program metrics shown and their alignment with peer performance. Rechtin stated the metrics reflect areas with the best longitudinal data and are broadly indicative of overall progress, while acknowledging threshold uncertainty.
- Benjamin Hendrix (RBC Capital Markets) asked about the rationale behind forming contingent pre-capitalized trusts (P-Caps) for liquidity. Mellet explained P-Caps increase liquidity flexibility without raising leverage unless drawn, and are a first in the health payer industry, offering low-cost, long-duration funding.
- Kevin Fischbeck (Bank of America) sought clarity on the strategy behind targeted plan exits for 2027 versus previous years. Mellet emphasized a focus on profitability by removing lower-return plans and protecting high-value segments, with margin progress prioritized over broad-based cuts.
Catalysts in Upcoming Quarters
In upcoming quarters, our analysts will closely monitor (1) the October release of CMS Stars ratings to validate whether operational improvements translate into higher bonus payments, (2) execution of the 2027 Medicare Advantage plan exits and the company’s ability to retain and recapture members, and (3) continued progress on cost reduction and process simplification initiatives. Developments in drug pricing trends and Medicaid expansion will also be important indicators for future performance.
Humana currently trades at $361.63, down from $388.71 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
